The plans she builds decide which gene therapies reach the patients who can't see. She started at the lab bench and never left the science behind.
Ophthalmic gene therapy is one of the most complicated corners of medicine. You are editing the instructions inside a single cell at the back of the eye, hoping to give someone their sight. The science is dazzling. Getting it to a patient is the hard part - a thousand quiet decisions between a good idea and a delivered treatment. Xuandai Nguyen makes those decisions for a living.
At Beacon Therapeutics, an ophthalmic gene therapy company built to restore and improve vision in people with rare and prevalent retinal diseases, Nguyen holds two of the harder jobs in the building at the same time: Vice President and Head of Global Program Strategy, and Chief of Staff to the CEO. One role sets the direction of the whole pipeline. The other keeps the person running the company on the same page as it.
She does not run the lab. She runs the map that tells the lab where to go - the strategy that decides which programs get resources, which questions get answered first, and how a fragile idea survives contact with reality.
It is a role you can only fill if you have lived on both sides of it. Nguyen has. She holds a Ph.D. and an MBA, a pairing that is rarer than it sounds and more useful than it looks. The doctorate taught her to ask the right question. The business degree taught her to make the right bet. Beacon gets both in one person.
She began where a lot of scientists begin and most strategists never do: elbows-deep in the work. From 1999 to 2002 she was a postdoctoral fellow at Stanford University, doing the slow, patient business of actual research. That grounding never wore off. It is the reason she can sit across from a research team and speak their language instead of translating it secondhand.
Then the canvas got bigger. At Genentech - the company that more or less invented the biotech industry - she moved into senior pipeline and portfolio strategy, working across immunology, ophthalmology and respiratory disease. This is the part of the business where you decide, with imperfect information and real money, which medicines the world gets to try.
From there the pattern held: senior commercial and strategy roles at Forma Therapeutics, where she led global marketing for a sickle cell disease program, and at ACELYRIN, where she ran commercial strategy and new product planning. Different diseases, different companies, one throughline - getting hard medicines to the people who need them most.
The companies change. The mission does not. In 2025 she brought all of it to Beacon and pointed it at the eye.
She speaks three languages - English, Vietnamese and French. She also speaks fluent drug development.
Two coasts trained her: Berkeley for undergrad, Cornell's Johnson School for the MBA.
She carries two demanding titles at once - program strategy chief and the CEO's right hand.
Her work has spanned immunology, ophthalmology, respiratory disease and sickle cell disease.
She joined industry and patient leaders at the Foundation Fighting Blindness "Investing in Cures" summit in Boston.
Strip away the titles and the org charts and there is a single, stubborn goal underneath: help bring gene therapies through development and into the hands of patients who are losing their sight. Inherited retinal diseases are cruel in their arithmetic - a single faulty gene, a slow fade to dark. The promise of gene therapy is that you can rewrite that arithmetic.
Nguyen's contribution is not a molecule. It is the plan that gets the molecule to a clinic without falling apart along the way. In a field crowded with brilliant science, that connective tissue is often what separates the therapies that reach people from the ones that stall in a slide deck.
The future of vision restoration will be written by a lot of hands. Some hold pipettes. Nguyen holds the plan that connects them all.
Profile compiled from public professional sources. Facts stated as verifiable; interpretive framing is editorial.
Xuandai Nguyen, Ph.D., MBA, is Vice President, Head of Global Program Strategy and Chief of Staff to the CEO at Beacon Therapeutics, an ophthalmic gene therapy company working to restore sight in people with inherited and prevalent retinal diseases. A scientist-turned-strategist, Nguyen has spent more than two decades moving medicines from bench to market, with senior roles at Genentech, Forma Therapeutics and ACELYRIN spanning immunology, ophthalmology, respiratory and sickle cell disease. Trilingual and Berkeley- and Cornell-trained, Nguyen sits at the intersection of hard science and commercial strategy, translating complicated biology into the plans that decide which therapies reach patients.
Last updated: